Common KRAS and NRAS Gene Mutations in Sporadic Colorectal Cancer in Northeastern Iranian Patients

Mutation analysis of the Epidermal Growth Factor Receptor (EGFR) downstream has been a main part of colorectal carcinoma evaluation. Large prospective clinical trials have shown only colorectal cancer (CRC) with wild-type KRAS and NRAS responds to anti- EGFR treatment. Hence, mutation analysis is necessary prior to treatment. It is essential to conduct studies to learn about the mutation signature of such tumors. The aim of this study was to evaluate the frequency of hotspot mutations in KRAS and NRAS genes in Iranian CRC patients and to explore their correlations with clinicopathological parameters.
Source: Current Problems in Cancer - Category: Cancer & Oncology Authors: Source Type: research